Akebia Therapeutics Announces That The American Journal Of Kidney Disease Has Published The Results Of FO2CUS, An Open-Label Study Evaluating The Efficacy And Safety Of Vadadustat, An Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, In...
Akebia Therapeutics Announces That The American Journal Of Kidney Disease Has Published The Results Of FO2CUS, An Open-Label Study Evaluating The Efficacy And Safety Of Vadadustat, An Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, In...
The article titled, "Vadadustat Three Times Weekly in Patients With Anemia Due to Dialysis-Dependent CKD," is available here.Akebia Therapeutics Announces That The American Journal Of Kidney Disease Has Published The Results Of FO2CUS, An Open-Label Study Evaluating The Efficacy And Safety Of Vadadustat, An Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, In Hemodialysis Patients Who Were Converted From A Long-Acting Erythropoiesis-stimulating Agent To 3-Times Weekly Oral Vadadustat Dosing For The Maintenance Treatment Of Anemia
Akebia Therapeutics宣佈，《美國腎臟病雜誌》公佈了 FO2CUS 的結果，這是一項開放標籤的研究，旨在評估口服缺氧誘導因子脯氨酰羥化酶抑制劑對從長效促紅素刺激劑轉化爲每週三次口服 Vadadustat 用於貧血維持治療的血液透析患者的療效和安全性
Akebia continues to publish important results of FO2CUS trial to further physicians' understanding of Vafseo (vadadustat)
Akebia 繼續公佈 FO2CUS 試驗的重要結果，以增進醫生對 Vafseo（vadadustat）的理解
CAMBRIDGE, Mass., Nov. 14, 2024 /PRNewswire/ -- Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the American Journal of Kidney Disease has published the results of FO2CUS, an open-label study evaluating the efficacy and safety of vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, in hemodialysis patients who were converted from a long-acting erythropoiesis-stimulating agent (ESA) to three times weekly oral vadadustat dosing for the maintenance treatment of anemia.
馬薩諸塞州劍橋，2024年11月14日 /PRNewswire/ — 旨在改善受腎臟疾病影響的人們生活的生物製藥公司Akebia Therapeutics, Inc.（納斯達克股票代碼：AKBA）今天宣佈，《美國腎臟病雜誌》公佈了 FO2CUS 的結果，這是一項評估口服缺氧誘導因子prolyl的療效和安全性的開放標籤研究羥化酶（HIF-PH）抑制劑，用於從長效紅細胞生成刺激劑（ESA）轉化爲每週三次口服 vadadustat 的血液透析患者用於維持治療貧血的劑量。
AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)" alt="Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)">
AKBA），一家專注於爲腎臟疾病患者開發和商業化療法的生物製藥公司（PRNewsFoto/AKEBIA Therapeutics, Inc.）” alt= 「AKEBIA Therapeutics, Inc.（納斯達克股票代碼：AKBA），一家專注於爲腎臟病患者開發和商業化療法的生物製藥公司（PRnewsFoto/AKEBIA Therapeutics, Inc.）」 alt= “AKEBIA Therapeutics, Inc.（納斯達克股票代碼：AKBA），一家專注於爲腎臟病患者開發和商業化療法的生物製藥公司（.) “>
The article titled, "Vadadustat Three Times Weekly in Patients With Anemia Due to Dialysis-Dependent CKD," is available here.
這篇題爲 「Vadadustat每週三次調查透析依賴性慢性肺病導致的貧血患者」 的文章可在此處查閱。
